Physicochemical characterization and phase I study of CMAB008, an infliximab biosimilar produced by a different expression system

BACKGROUND: Infliximab (Remicade), a chimeric monoclonal antibody against human TNFα, will inevitably face competition from biosimilar products, because of its effectiveness in autoimmune diseases and rapidly increasing market demand. According to guidelines for biosimilar development, the “biosimil...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Drug Des Devel Ther
Egile Nagusiak: An, Qing, Zheng, Yingxin, Zhao, Yirong, Liu, Tao, Guo, Huaizu, Zhang, Dapeng, Qian, Weizhu, Wang, Hao, Guo, Yajun, Hou, Sheng, Li, Jing
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Dove Medical Press 2019
Gaiak:
Clinical Trial Report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6420106/
https://ncbi.nlm.nih.gov/pubmed/30880912
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S170913
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak